Seastar Medical Holding CORP (ICUCW) — SEC Filings

Overview

Seastar Medical Holding CORP (ICUCW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEF 14A filed on Nov 14, 2025: SeaStar Medical Holding Corp (ICUCW) is convening a Special Meeting of Stockholders on December 18, 2025, to address critical corporate governance matters. The primary proposal, the Reverse Stock Split Proposal, seeks approval for a 1-for-10 reverse stock split of its common stock, par value $0.0001

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 6 bearish, 42 neutral, 2 mixed. The dominant filing sentiment for Seastar Medical Holding CORP is neutral.

Filing Type Overview

Seastar Medical Holding CORP (ICUCW) has filed 2 8-K/A, 33 8-K, 4 DEF 14A, 4 10-Q, 3 S-1, 1 S-1/A, 2 10-K/A, 1 SC 13G with the SEC between Jun 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

• 8-K/A Filing — 8-K/A · Dec 23, 2025
• 8-K Filing — 8-K · Dec 18, 2025
• 8-K Filing — 8-K · Nov 17, 2025
• SeaStar Medical Seeks 1-for-10 Reverse Split, Authorized Share Reduction — DEF 14A · Nov 14, 2025 Risk: high
  SeaStar Medical Holding Corp (ICUCW) is convening a Special Meeting of Stockholders on December 18, 2025, to address critical corporate governance matters. The
• SeaStar Medical Narrows Losses, Boosts Revenue Amidst Going Concern Warning — 10-Q · Nov 13, 2025 Risk: high
  SeaStar Medical Holding Corporation (ICUCW) reported a net loss of $3.47 million for the three months ended September 30, 2025, an improvement from a $4.48 mill
• SeaStar Medical Holding Corp. Announces Board and Executive Changes — 8-K · Sep 29, 2025 Risk: medium
  SeaStar Medical Holding Corp. announced on September 23, 2025, changes in its board of directors and executive compensation arrangements. The filing details the
• SeaStar Medical Files 8-K — 8-K · Sep 24, 2025 Risk: low
  SeaStar Medical Holding Corp. filed an 8-K on September 24, 2025, reporting other events and financial statements. The company, formerly known as LMF Acquisitio
• SeaStar Medical: Board & Executive Compensation Changes — 8-K · Aug 19, 2025 Risk: medium
  SeaStar Medical Holding Corp. announced on August 13, 2025, changes related to its board of directors and executive compensation. Specifically, the company elec
• SeaStar Medical Files 8-K/A Amendment — 8-K/A · Aug 14, 2025 Risk: low
  SeaStar Medical Holding Corp. filed an 8-K/A on August 14, 2025, to amend a previous filing related to its results of operations and financial condition. The am
• SeaStar Medical Files 8-K on Asset Acquisition/Disposition — 8-K · Aug 13, 2025 Risk: medium
  SeaStar Medical Holding Corp. filed an 8-K on August 13, 2025, reporting the completion of an acquisition or disposition of assets. The filing indicates the com
• SeaStar Medical Files S-1 for Continuous Offering — S-1 · Aug 8, 2025 Risk: medium
  SeaStar Medical Holding Corp (ICUCW) filed an S-1 registration statement on August 8, 2025, for a delayed or continuous offering of securities under Rule 415. T
• SeaStar Medical Holding Corp. Files 8-K — 8-K · Aug 8, 2025 Risk: medium
  SeaStar Medical Holding Corp. filed an 8-K on August 8, 2025, reporting an event under 'Other Events'. The filing does not contain specific details about the ev
• SeaStar Medical Faces Nasdaq Delisting Warning — 8-K · Aug 6, 2025 Risk: high
  SeaStar Medical Holding Corp. announced on June 26, 2023, that it received a notice from The Nasdaq Stock Market indicating a failure to meet continued listing
• SeaStar Medical Files 8-K: Material Agreement & Equity Sales — 8-K · Aug 1, 2025 Risk: medium
  SeaStar Medical Holding Corp. entered into a material definitive agreement on July 31, 2025. The company also reported on unregistered sales of equity securitie
• SeaStar Medical Board & Officer Changes Announced — 8-K · Jul 16, 2025 Risk: medium
  SeaStar Medical Holding Corp. announced on July 14, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company r
• SeaStar Medical Files 8-K: Material Agreement & Equity Sales — 8-K · Jul 14, 2025 Risk: medium
  SeaStar Medical Holding Corp. entered into a material definitive agreement on July 10, 2025. The company also disclosed unregistered sales of equity securities
• SeaStar Medical Holding Corp. Reports on Shareholder Vote Matters — 8-K · Jul 8, 2025 Risk: low
  SeaStar Medical Holding Corp. filed an 8-K on July 8, 2025, reporting on matters submitted to a vote of security holders as of July 3, 2025. The filing indicate
• SeaStar Medical to Acquire InfuMetrics for $15M — 8-K · Jul 2, 2025 Risk: medium
  SeaStar Medical Holding Corp. announced on July 1, 2025, that it has entered into a definitive agreement to acquire all of the outstanding equity interests of I
• SeaStar Medical Reports Definitive Agreement, Officer Changes — 8-K · Jun 23, 2025 Risk: medium
  On June 17, 2025, SeaStar Medical Holding Corporation entered into a material definitive agreement, likely related to its financing or operations. The company a
• SeaStar Medical Amends S-1 for Continuous Offering — S-1/A · Jun 20, 2025 Risk: medium
  SeaStar Medical Holding Corp (ICUCW) filed an S-1/A on June 20, 2025, primarily to register securities for a delayed or continuous offering under Rule 415. The
• SeaStar Medical Files S-1 for Continuous Offering — S-1 · Jun 16, 2025 Risk: medium
  SeaStar Medical Holding Corp (ICUCW) filed an S-1 registration statement on June 16, 2025, for a delayed or continuous offering of securities under Rule 415. Th
• SeaStar Medical Holding Corp. Files 8-K on Board and Officer Changes — 8-K · Jun 11, 2025 Risk: medium
  SeaStar Medical Holding Corp. filed an 8-K on June 11, 2025, reporting on events as of June 6, 2025. The filing primarily concerns the departure of directors, e
• SeaStar Medical Files S-1 Registration — S-1 · May 19, 2025 Risk: medium
  SeaStar Medical Holding Corporation filed an S-1 registration statement on May 19, 2025, for its securities. The company, formerly known as LMF Acquisition Oppo
• SeaStar Medical 10-Q: Equity Line, Warrants Detailed — 10-Q · May 14, 2025 Risk: medium
  SeaStar Medical Holding Corp. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position, including details on common s
• SeaStar Medical Files Definitive Proxy Statement — DEF 14A · May 6, 2025 Risk: low
  SeaStar Medical Holding Corp. filed a Definitive Proxy Statement (DEF 14A) on May 7, 2025, for the fiscal year ending December 31, 2025. The company, formerly k
• SeaStar Medical Files 8-K: Definitive Agreement & Equity Sales — 8-K · Apr 25, 2025 Risk: medium
  SeaStar Medical Holding Corp. announced on April 25, 2025, the entry into a material definitive agreement and unregistered sales of equity securities. The filin
• SeaStar Medical Holding Corp. Files 2024 Annual Report Amendment — 10-K/A · Apr 23, 2025 Risk: low
  SeaStar Medical Holding Corp. filed an amendment (10-K/A) on April 23, 2025, for its fiscal year ending December 31, 2024. The company, formerly LMF Acquisition
• SeaStar Medical Holding Corp. Files 8-K on Shareholder Votes — 8-K · Mar 28, 2025 Risk: low
  SeaStar Medical Holding Corp. filed an 8-K on March 28, 2025, to report on matters submitted to a vote of its security holders. The filing details the company's
• SeaStar Medical Files 8-K on Financials — 8-K · Mar 27, 2025 Risk: low
  SeaStar Medical Holding Corp. filed an 8-K on March 27, 2025, reporting on its results of operations and financial condition. The filing includes financial stat
• SeaStar Medical Holding Corp. Files 8-K on Shareholder Vote Matters — 8-K · Mar 21, 2025 Risk: medium
  SeaStar Medical Holding Corp. filed an 8-K on March 21, 2025, reporting on a submission of matters to a vote of security holders as of March 20, 2025. The compa
• SeaStar Medical to Acquire ImmunoChemistry Assets — 8-K · Mar 13, 2025 Risk: medium
  SeaStar Medical Holding Corp. announced on March 11, 2025, that it has entered into a definitive agreement to acquire substantially all of the assets of ImmunoC
• SeaStar Medical Holding Corp Files Definitive Proxy Statement — DEF 14A · Feb 28, 2025 Risk: low
  SeaStar Medical Holding Corp filed a definitive proxy statement (DEF 14A) on February 28, 2025, for the period ending March 20, 2025. The company, formerly know
• SeaStar Medical Files 8-K: Material Agreement & Equity Sales — 8-K · Feb 3, 2025 Risk: medium
  SeaStar Medical Holding Corp. entered into a material definitive agreement on January 31, 2025. The company also disclosed unregistered sales of equity securiti
• SeaStar Medical Faces Nasdaq Delisting Notice — 8-K · Jan 31, 2025 Risk: high
  SeaStar Medical Holding Corp. announced on January 28, 2025, that it received a notice from the Nasdaq Stock Market indicating a failure to meet continued listi
• 8-K Filing — 8-K · Jan 13, 2025
• SeaStar Medical Faces Nasdaq Delisting Warning — 8-K · Dec 26, 2024 Risk: high
  SeaStar Medical Holding Corp. announced on December 24, 2024, that it received a notice from The Nasdaq Stock Market indicating a failure to meet continued list
• SeaStar Medical Sells Assets to Trive Capital Affiliate — 8-K · Dec 19, 2024 Risk: medium
  SeaStar Medical Holding Corp. announced on December 13, 2024, that it has entered into a definitive agreement to sell its assets to an affiliate of its largest
• SeaStar Medical Holding Corp. Files 8-K on Security Holder Votes — 8-K · Nov 26, 2024 Risk: low
  SeaStar Medical Holding Corp. filed an 8-K on November 26, 2024, to report on matters submitted to a vote of its security holders. The filing details the compan
• SC 13G Filing — SC 13G · Nov 14, 2024
• SeaStar Medical Holding Corp. Files Q3 2024 10-Q — 10-Q · Nov 13, 2024 Risk: medium
  SeaStar Medical Holding Corp. filed its 10-Q for the period ending September 30, 2024. The company reported financial results and provided updates on its operat
• SeaStar Medical Holding Corp. Files Definitive Proxy Statement — DEF 14A · Nov 4, 2024 Risk: low
  SeaStar Medical Holding Corp. filed a Definitive Proxy Statement (DEF 14A) on November 4, 2024, for its annual meeting on November 26, 2024. The company, former
• SeaStar Medical Sells Assets, Eyes Q1 2025 Close — 8-K · Oct 22, 2024 Risk: high
  SeaStar Medical Holding Corp. announced on October 20, 2024, that it has entered into a definitive agreement to sell its assets to an undisclosed buyer. The com
• SeaStar Medical Holding Corp. Files 8-K — 8-K · Aug 21, 2024 Risk: medium
  SeaStar Medical Holding Corp. entered into a material definitive agreement on August 20, 2024. The company, formerly known as LMF Acquisition Opportunities Inc.
• SeaStar Medical Files Q2 10-Q Amidst Note/Warrant Activity — 10-Q · Aug 13, 2024 Risk: medium
  SeaStar Medical Holding Corp. filed its 10-Q for the period ending June 30, 2024. The company reported a net loss for the quarter and highlighted ongoing effort
• SeaStar Medical Files 8-K: Material Agreement & Equity Sales — 8-K · Jul 11, 2024 Risk: medium
  SeaStar Medical Holding Corp. entered into a material definitive agreement on July 10, 2024. The company also disclosed unregistered sales of equity securities
• SeaStar Medical Sells SCD Tech to Unaffiliated Buyer — 8-K · Jul 9, 2024 Risk: medium
  SeaStar Medical Holding Corporation announced on July 5, 2024, that it has entered into a definitive agreement to sell its Selective Cytopheretic Device (SCD) t
• SeaStar Medical to be Delisted from Nasdaq — 8-K · Jul 5, 2024 Risk: high
  SeaStar Medical Holding Corp. announced on July 3, 2024, that it received a notice from the Nasdaq Stock Market indicating a failure to meet continued listing r
• SeaStar Medical Files 2023 Annual Report Amendment — 10-K/A · Jul 3, 2024 Risk: medium
  SeaStar Medical Holding Corp. filed an amendment (No. 2) to its 2023 annual report on July 3, 2024. The company, incorporated in Delaware with its principal off
• SeaStar Medical Enters Material Definitive Agreement — 8-K · Jul 2, 2024 Risk: medium
  On June 28, 2024, SeaStar Medical Holding Corp. entered into a material definitive agreement. The company, formerly known as LMF Acquisition Opportunities Inc.
• SeaStar Medical Faces Nasdaq Delisting Notice — 8-K · Jun 28, 2024 Risk: high
  SeaStar Medical Holding Corp. received a notice on June 24, 2024, indicating it failed to meet a continued listing rule or standard for the Nasdaq Capital Marke

Risk Profile

Risk Assessment: Of ICUCW's 45 recent filings, 8 were flagged as high-risk, 27 as medium-risk, and 10 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Seastar Medical Holding CORP's most recent 10-Q filing (Nov 13, 2025):

• Revenue: $814K
• Net Income: $-9.25M
• EPS: $-0.60
• Debt-to-Equity: 0.35
• Cash Position: $13.76M
• Operating Margin: -1125.25%
• Total Assets: $15.53M
• Total Debt: $4.07M

Key Executives

• Eric Schlorff
• Chief Executive Officer
• Joshua Erekson
• Daniel Lyman
• Joseph M. Lucosky
• Steven A. Lipstein

Industry Context

SeaStar Medical operates in the biotechnology and medical device sector, a highly competitive and innovation-driven industry. Companies in this space often face significant R&D costs, lengthy regulatory approval processes, and the need for substantial capital to fund growth and commercialization. Success hinges on developing proprietary technologies and securing market adoption against established players and emerging startups.

Top Tags

material-agreement (7) · corporate-governance (6) · delisting (5) · nasdaq (5) · equity-sale (5) · SEC Filing (4) · Medical Devices (4) · regulatory-filing (4) · compliance (4) · shareholder-vote (4)

Key Numbers

• Reverse Stock Split Ratio: 1-for-10 — Proposed ratio for the reverse stock split of common stock
• New Authorized Shares: 425,000,000 — Proposed total number of authorized shares of common stock after reduction
• Shares Reduced: 25,000,000 — Number of authorized shares of common stock to be reduced
• Outstanding Shares: 35,865,834 — Shares of Common Stock outstanding and entitled to vote as of November 3, 2025
• Quorum Requirement: 11,955,278 — Number of shares required for a quorum (33 1/3% of outstanding shares)
• Par Value per Share: $0.0001 — Par value of SeaStar Medical's common stock
• Discretionary Period: 1 year — Timeframe within which the Board can effect the reverse stock split
• Record Date: November 3, 2025 — Date for determining stockholders eligible to vote at the Special Meeting
• Special Meeting Date: December 18, 2025 — Date when stockholders will vote on the proposals
• Meeting Time: 10 am MST — Scheduled start time for the virtual Special Meeting
• Cash: $13.76M — Increased from $1.82 million at December 31, 2024, providing short-term liquidity but insufficient for 12 months.
• Accumulated Deficit: $148.8M — As of September 30, 2025, indicating significant historical losses.
• Net Loss (9 months): $9.25M — For the nine months ended September 30, 2025, a substantial improvement from $20.41 million in the prior year.
• Net Revenue (9 months): $814K — For the nine months ended September 30, 2025, a significant increase from $68,000 in the prior year, driven by QUELIMMUNE.
• Net Cash Provided by Financing Activities: $21.45M — For the nine months ended September 30, 2025, a primary source of cash inflow.

Related Companies

ICU · SEA

Frequently Asked Questions